Calibr, A Division Of Scripps Research
Clinical trials sponsored by Calibr, A Division Of Scripps Research, explained in plain language.
-
Promising autoimmune therapy trial pulled before it even started
Disease control TerminatedThis study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Gene therapy patients monitored for 15 years in safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 40 people who have already received CLBR001, a gene therapy using a lentiviral vector. Researchers will track participants for 15 years to watch for any delayed side effects or safety concerns. The goal is to better understand the long-term risks of this type o…
Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:49 UTC